Sevabertinib

DRUG3 trials

Sponsors

Bayer

Conditions

Advanced Non-small Cell Lung CancerAdvanced Non-small Cell Lung Cancer, HER2 MutationCancerDrug MetabolismHepatic InsufficiencyLiver DiseasesPharmacokinetics

Phase 1

A Study Evaluating How Moderate Liver Impairment Affects the Absorption, Distribution, Metabolism, and Elimination of Sevabertinib After a Single Oral Dose

CompletedNCT07102095

BayerDrug Metabolism, Hepatic Insufficiency, Liver Diseases +1

Start: 2025-07-24End: 2025-12-03Updated: 2026-02-10

Phase 3

A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

RecruitingNCT06452277

BayerAdvanced Non-small Cell Lung Cancer, HER2 Mutation

Start: 2024-08-28End: 2029-06-27Target: 444Updated: 2026-09-10

Unknown Phase

Expanded Access to Provide Sevabertinib (BAY 2927088) for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 Mutation

BayerAdvanced Non-small Cell Lung Cancer, Cancer

Updated: 2026-07-07

Related Papers

SOHO-02: Phase III trial of BAY 2927088 in patients with locally advanced or metastatic NSCLC with <i>HER2</i> -activating mutations.

Journal of Clinical Oncology2025-05-281 citations

Abstract 5610: BAY 2927088: a novel treatment option for patients with NSCLC with <i>HER2</i> mutations

Cancer Research2025-04-21